{"id":372624,"date":"2025-08-25T15:28:16","date_gmt":"2025-08-25T15:28:16","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/372624\/"},"modified":"2025-08-25T15:28:16","modified_gmt":"2025-08-25T15:28:16","slug":"uk-terumo-to-acquire-organox-for-us1-5bn-in-one-of-the-largest-ever-deals-in-the-uk-medtech-sector","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/372624\/","title":{"rendered":"UK: Terumo to acquire OrganOx for US$1.5bn in one of the largest-ever deals in the UK medtech sector"},"content":{"rendered":"

Tokyo-listed, Terumo<\/a>, is a global medical device company originating from Japan, is acquiring OrganOx<\/a>, a UK-based innovator in organ preservation devices, in a transaction valued at approximately US$1.5bn.<\/p>\n

With a transaction value of over \u00a31bn, it is one of the largest-ever deals in the UK medtech sector and one of the biggest spinouts from Oxford University.<\/p>\n

A commercial stage organ technology company spun out of the University of Oxford in 2008 by Professor Peter Friend and Professor Constantin Coussios<\/a>, OrganOx specializes in advanced normothermic machine perfusion (NMP) devices for organ preservation. Approved in the US, EU, UK, Canada, and Australia, the OrganOx\u00a0metra\u00a0NMP platform technology has been utilized in over 6,000 liver transplants to date. It keeps donor livers in a metabolically active state outside the body, providing transplant teams the opportunity for functional assessment of the organ prior to transplant and leads to an increased number of organs available for transplant.<\/p>\n

The acquisition marks Terumo\u2019s strategic entry into the organ transplantation-related sector. By combining Terumo\u2019s expertise in designing medical devices and equipment with OrganOx\u2019s advanced capabilities in NMP, the company aims to deliver innovative organ preservation devices globally and broaden access for patients in need of transplants.<\/p>\n

\u201cOrgan transplantation represents a last resort for patients with limited treatment options, and addressing the unmet needs in this area carries significant social value,\u201d said Hikaru Samejima<\/a>, CEO of Terumo Corporation. \u201cDonated organs are an extremely precious medical resource, and OrganOx\u2019s mission to deliver transplantable organs in optimal condition deeply resonates with our unwavering commitment to patients.<\/p>\n

Terumo has already made a strategic investment via its corporate venture capital arm, Terumo Ventures, in March 2025 alongside Intuitive Ventures and Piper Heartland Healthcare when OrganOx completed a second closing of a private placement.<\/p>\n

\u201cThis transaction represents an important milestone for OrganOx and its shareholders,\u201d said Craig Marshall<\/a>, CEO of OrganOx. \u201cWe look forward to continuing our rich history of collaboration with Terumo to continue harnessing our collective innovations to improve patient care.\u201d<\/p>\n

The second closing brought total fund raising in primary and secondary equity financing to US$160m\u00a0following the first close in February 2025<\/a>.<\/p>\n

In 2023, the firm raised\u00a0\u00a325m in a growth<\/a> round, led by Lauxera. In 2020, it received a\u00a0\u00a34.6m investment from BGF<\/a>. It raised \u00a31.5m in a Series A round in 2008, led by Oxford Technology Management and Technikos. The Oxford University Challenge Seed Fund also participated in the round.<\/p>\n

\u201cThank you to our top tier group of investors, including among others Business Growth Fund (BGF), Lauxera Capital, HealthQuest Capital, Sofina, Oxford University, Longwall Ventures, Technikos, Oxford Investment Consultants, and Intuitive Ventures who provided both the capital and leadership to enable the value creation inherent in today\u2019s announced US$1.5bn transaction,\u201d said Steve Deitsch<\/a>, OrganOx\u2019s CFO.<\/p>\n

This transaction will represent Lauxera\u2019s first exit as an emerging healthcare specialist private equity manager. France based Lauxera was founded in 2020.<\/p>\n

\u201cIt has been an honour supporting Organox\u2019s outstanding growth through sweat, coaching, and unwavering belief in the transformative potential of the company,\u201d said Lauxera co-founding partner, Samuel Levy<\/a>, who joined the Organox board following its 2023 investment. \u201cSince our initial investment roughly two years ago, Organox has multiplied its revenue more than five-fold. We feel privileged to have had the opportunity to intensely support this successful US commercialization scale-up.\u201d<\/p>\n

For BGF, the largest shareholder in OrganOx\u00a0<\/strong>and supporter of the company through seven rounds of investment since 2019, the sale marks\u00a0its largest-ever return\u00a0generating proceeds of \u00a3175m and representing a\u00a010x money multiple\u00a0on its initial investment and an\u00a0overall IRR in the region of 69%.<\/p>\n

\u201cAt a ten-figure valuation, we are incredibly proud to have played a key role in one of the UK\u2019s largest medtech exits,\u201d said Andy Gregory<\/a>, CEO of BGF. \u201cIt reflects a remarkable achievement by the OrganOx team, and we are especially proud that this success is tied directly to a positive impact in patient outcomes. \u201cBy combining early and growth-stage investing across multiple sectors, BGF has created the right blend to deliver strong, sustainable and repeatable returns. Our ambition now is for more capital to flow into the UK\u2019s most promising companies \u2014 whether through co-investments with international, specialist investors, or domestic sources.\u201d<\/p>\n

Perella Weinberg Partners and Piper Sandler served as OrganOx\u2019s financial advisors and Latham & Watkins acted as legal counsel to OrganOx.<\/p>\n

Press release: News \u2013 OrganOx<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Tokyo-listed, Terumo, is a global medical device company originating from Japan, is acquiring OrganOx, a UK-based innovator in…\n","protected":false},"author":2,"featured_media":372625,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4316],"tags":[121491,130385,130386,130387,105,4348,130388,130389,130390,130391,130392,130393,130394,130395,130396,942,130397,130398,130399,130400,130401,130402,9865,130403,130404,16,15],"class_list":{"0":"post-372624","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-andy-gregory","9":"tag-business-growth-fund-bgf","10":"tag-constantin-coussios","11":"tag-craig-marshall","12":"tag-health","13":"tag-healthcare","14":"tag-healthquest-capital","15":"tag-hikaru-samejima","16":"tag-intuitive-ventures","17":"tag-latham-watkins","18":"tag-lauxera-capital-partners","19":"tag-longwall-ventures","20":"tag-organox","21":"tag-oxford-investment-consultants","22":"tag-oxford-technology-management","23":"tag-oxford-university","24":"tag-oxford-university-challenge-seed-fund","25":"tag-perella-weinberg-partners","26":"tag-peter-friend","27":"tag-piper-heartland-healthcare","28":"tag-piper-sandler","29":"tag-samuel-levy","30":"tag-sofina","31":"tag-steve-deitsch","32":"tag-terumo","33":"tag-uk","34":"tag-united-kingdom"},"share_on_mastodon":{"url":"","error":"Validation failed: Text character limit of 500 exceeded"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/372624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=372624"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/372624\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/372625"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=372624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=372624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=372624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}